😎 Summer Sale Exclusive - Up to 50% off AI-powered stock picks by InvestingProCLAIM SALE

Avantor shares edge up on earnings beat

EditorRachael Rajan
Published 04/26/2024, 07:11 AM
© Reuters.
AVTR
-

RADNOR, Pa. – Avantor, Inc. (NYSE: NYSE:AVTR), a global provider of mission-critical products and services to the life sciences and advanced technology sectors, reported a slight uptick in its stock by 0.64% after announcing first-quarter earnings that modestly exceeded analyst expectations.

The company posted adjusted earnings per share (EPS) of $0.22, just above the $0.20 consensus. Meanwhile, revenue met the analyst projections, coming in at $1.68 billion for the quarter.

In comparison to the same period last year, Avantor experienced a 5.6% decline in net sales, with organic sales dropping by 6.3%. Despite the decrease in sales, the company's leadership remains positive.

"The year is off to a good start as first quarter organic revenue growth was in line with our guidance and disciplined execution drove outperformance on margins and profitability," said Michael Stubblefield, President and Chief Executive Officer. He also highlighted the company's progress in implementing a new operating model and a multi-year cost transformation initiative, which aims to unlock efficiencies and better align with customer needs.

The company's net income saw a significant decrease to $60.4 million from $121.5 million in the first quarter of the previous year. The adjusted net income also fell to $150.6 million from $195.4 million in the prior year's comparable period. Despite these declines, Avantor's adjusted EBITDA stood at $283 million with a margin of 16.8%, and the adjusted operating income margin was reported at 15.4%.

The Laboratory Solutions segment reported a 3.8% decrease in net sales, while the Bioscience Production segment experienced a more pronounced 9.5% drop. Both segments also saw declines in their adjusted operating income and margins compared to the first quarter of the previous year.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.